© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Effects of ApoE Genotype on ApoB-48 and ApoB-100 Kinetics With Stable Isotopes in Humans
Presented in part at the 71st Scientific Sessions of the American Heart Association, Dallas, Tex, November 9, 1998, and published in abstract form in Circulation. 1998;98(suppl I):I-239.
From the Lipid Metabolism Laboratory (F.K.W., A.H.L., J.L.J., G.G.D., E.J.S.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Mass, and Population Kinetics (P.H.R.B.), Department of Bioengineering, University of Washington, Seattle.
Correspondence to Francine K. Welty, Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111. E-mail fwelty{at}caregroup.harvard.edu
Abstract—Subjects with the apolipoprotein (apo) E4 allele have been shown to have higher low density lipoprotein (LDL) cholesterol and apoB levels than do subjects with the other alleles. To elucidate the metabolic mechanisms responsible for this finding, we examined the kinetics of apoB-48 within triglyceride-rich lipoproteins (TRLs) and of apoB-100 within very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and LDL by using a primed constant infusion of [5,5,5-2H3]leucine in the fed state (hourly feeding) during consumption of an average American diet in 18 normolipidemic subjects, 12 of whom had the apoE3/E3 genotype and 6, the apoE3/E4 genotype. Lipoproteins were isolated by ultracentrifugation and apolipoproteins, by sodium dodecyl sulfate gels; isotope enrichment was assessed by gas chromatography–mass spectrometry. Kinetic parameters were calculated by multicompartmental modeling of the data with SAAM II software. Compared with the apoE3/E3 subjects, the apoE3/E4 subjects had significantly higher levels of total apoB, 100.1±17.8 versus 135.4±34.0 mg/dL (P=0.009), and significantly higher levels of LDL apoB-100, 88.1±19.2 versus 127.5±32.7 mg/dL (P=0.005), respectively. The pool size of TRL apoB-48 was 17.4% lower for apoE3/E4 subjects compared with apoE3/E3 subjects due to a 33.3% lower production rate (P=0.28). There was no significant difference in the TRL apoB-48 fractional catabolic rate (5.1±2.2 versus 5.0±2.1 pools per day). The pool size for VLDL apoB-100 was 36% lower for apoE3/E4 subjects compared with apoE3/E3 subjects due entirely to a 30% lower production rate (P=0.04). The LDL apoB-100 pool size was 57.8% higher (P=0.003) for apoE3/E4 subjects compared with apoE3/E3 subjects due to a 35.5% lower fractional catabolic rate of LDL apoB-100 (P=0.003), with no significant difference in production rate. In addition, 77% of VLDL apoB-100 was converted to LDL apoB-100 in apoE3/E4 subjects compared with 58% in apoE3/E3 subjects (P=0.05). In conclusion, the presence of 1 E4 allele was associated with higher LDL apoB-100 levels owing to lower fractional catabolism of LDL apoB-100 and a 33% increase in the conversion of VLDL apoB-100 to LDL apoB-100.
Key Words: apolipoprotein B • apolipoprotein E • stable isotopes • LDL cholesterol • lipoprotein kinetics
This article has been cited by other articles:
 |
|
 |
|
  J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism J. Lipid Res., March 1, 2008; 49(3): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zheng, K. Ikewaki, B. W. Walsh, and F. M. Sacks Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat J. Lipid Res., August 1, 2006; 47(8): 1771 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Proteggente, R. Turner, J. Majewicz, G. Rimbach, A. M. Minihane, K. Kramer, and J. K. Lodge Noncompetitive Plasma Biokinetics of Deuterium-Labeled Natural and Synthetic {alpha}-Tocopherol in Healthy Men with an apoE4 Genotype J. Nutr., May 1, 2005; 135(5): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Tremblay, B. Lamarche, I. L. Ruel, J.-C. Hogue, J. Bergeron, C. Gagne, and P. Couture Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation J. Lipid Res., May 1, 2004; 45(5): 866 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. C. M. T. Prinsen, J. A. Romijn, P. H. Bisschop, M. M. J. de Barse, P. H. R. Barrett, M. Ackermans, R. Berger, T. J. Rabelink, and M. G. M. de Sain-van der Velden Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans J. Lipid Res., July 1, 2003; 44(7): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Schaefer Lipoproteins, nutrition, and heart disease Am. J. Clinical Nutrition, February 1, 2002; 75(2): 191 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Raffai, L.-M. Dong, R. V. Farese Jr., and K. H. Weisgraber Introduction of human apolipoprotein E4 ""domain interaction"" into mouse apolipoprotein E PNAS, September 5, 2001; (2001) 201279298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Mensenkamp, B. Teusink, J. F.W. Baller, H. Wolters, R. Havinga, K. W. van Dijk, L. M. Havekes, and F. Kuipers Mice Expressing Only the Mutant APOE3Leiden Gene Show Impaired VLDL Secretion Arterioscler Thromb Vasc Biol, August 1, 2001; 21(8): 1366 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Raffai, L.-M. Dong, R. V. Farese Jr., and K. H. Weisgraber Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E PNAS, September 25, 2001; 98(20): 11587 - 11591. [Abstract] [Full Text] [PDF]
|
|